TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03329677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transference-focused Psychotherapy (TFP)
Description: Participants receive 18 months of bi-weekly TFP. Each sessions lasts 45 minutes. During sessions, a therapist employs assorted psychodynamic techniques tailored specially for symptoms and relational difficulties associated with BPD. A participant processes interpersonal experiences with her therapist in sessions alongside her therapist and gains therapeutic insight into her problematic ways of relating to her self and others.
Study: NCT04016155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott FreeStyle Libre
Description: Flash CGMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Own SMBG
Description: Market SMBG
Study: NCT04263038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Anticoagulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug without active agent
Study: NCT00681668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 150-800 mg, oral, twice a day (bid)
Study: NCT00862836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 100mg doses orally, once daily
Study: NCT03019419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 4mg/d or 8mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 4mg/d or 8mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04554719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-FAPI
Description: Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-FAPI dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
Study: NCT03762681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7239958
Description: Solution for injection, subcutaneous use (SC).
Study: NCT04554719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Each subject undergoes PET/MR imaging within 40-60 minutes after injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
Study: NCT01755377

Intervention type: DRUG
Intervention: Benznidazole
Study: NCT03762681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium chloride solution for injection, SC
Study: NCT03095469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24h after PCI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%NaCl solution
Description: when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
Study: NCT02868606

Intervention type: OTHER
Intervention: Physiologic Insulin Therapy

Intervention type: OTHER
Intervention: Sliding-Scale Insulin Therapy

Intervention type: OTHER
Intervention: Sliding-Scale Insulin Therapy

Intervention type: OTHER
Intervention: Sliding-Scale Insulin Therapy
Study: NCT02859740

Intervention type: OTHER
Intervention: SIGAM Questionnaire

Intervention type: OTHER
Intervention: SIGAM Questionnaire
Study: NCT00611975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
Study: NCT03882086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot reflexology
Description: Four sessions foot reflexology was applied for 15 minutes in each foot, every other days between postpartum 14th- 20th day
Study: NCT04411056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Barrier box
Description: Placement of barrier box ( a plastic box for shielding)
Study: NCT03762681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium chloride solution for injection, SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium chloride solution for injection, SC
Study: NCT04175041

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Study: NCT02303197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChiNing decoction
Description: ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
Study: NCT00003896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02858024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 and no tampons
Description: Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 with tampons
Description: followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 with no menses
Description: Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 with no menses
Description: Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 and same ring inserted after menses
Description: Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 and new ring inserted after menses
Description: Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
Study: NCT04127396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW)\>60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW\<60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization(TACE)
Description: TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib capsules will be administered orally, 400 mg twice daily (BID) oral dosing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization(TACE)
Description: TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
Study: NCT03130270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate tablet
Description: Patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC) after second-line treatment are assigned to receive apatinib mesylate tablet. A treatment cycle was defined as 28 days (4 weeks). The starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd). All patients continuous treatment until progression disease or non-tolerated toxicity.~Note: good tolerance was defined that no grade 3/4 hematology or/and non hematologic side effects occurred within 4 weeks after initiation treatment; poor tolerance was defined that grade 3/4 hematology or/and non hematologic side effects appeared within 4 weeks after initiation treatment.
Study: NCT02559570

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIN Dose A
Description: Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIN Dose B
Description: Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIN Dose C
Description: Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIN 145 µg
Description: Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
Study: NCT00722683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging with Contrast
Description: An ultrasound contrast agent, Definity, will be administered started through the IV line already in use. The imaging will be performed to map vascular flow.~The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times.
Study: NCT01396551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of anchored Beacon transponder in the lung
Description: Anchored Beacon transponder has an anchoring feature to secure it in the small airways of the lung.
Study: NCT02648464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02335385

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single incision laparoscopic varicocelectomy
Description: bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional transperitoneal laparoscopic varicocelectomy
Description: bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
Study: NCT01189461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaptanib sodium
Description: Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
Study: NCT02555085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB063
Description: Single ascending IV dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB063
Description: Single ascending IV dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB063
Description: Single ascending IV dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB063
Description: Single ascending IV dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB063
Description: Single ascending IV dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB063
Description: Single ascending IV dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB063
Description: Single ascending IV dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB063
Description: Single ascending IV dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose
Study: NCT01219192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: M2ES IV D1,8,15,21 every 28 days a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: M2ES IV D1,8,15,21, every 28days a cyce.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES
Description: M2ES 45mg IV D1,8,15,22 28days a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 60mg
Description: M2ES 60mg IV D1,8,15,22 every 28days a cycle
Study: NCT01215149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Study: NCT05029258

Intervention type: PROCEDURE
Intervention: Biopsy of tumour
Description: Cervical tumour biopsy during treatment. This will be used for gene expression (RNA) analysis against a hypoxia associated gene signature.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans
Description: Multiple magnetic resonance imaging (MRI) scans before and during treatment using oxygen enhanced (OE) / tissues oxygen level dependent (TOLD) sequence
Study: NCT01285479

Intervention type: DRUG
Intervention: Fingolimod
Description: fingolimod 0.5 mg/day, including generic versions of fingolimod
Study: NCT04188548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor (AI)
Description: Anastrozole or Exemestane or Letrozole administered orally (physician choice)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Administered intravenously
Study: NCT04299243

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact Lenses
Description: Contact lenses for vision correction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact Lenses
Description: Contact lenses for vision correction
Study: NCT03811990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cleveland Clinic Stress Free Now Meditations For Healers
Description: Phone-based meditation application
Study: NCT01606423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally, single dose
Study: NCT01215149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
Study: NCT01606423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally, single dose
Study: NCT04297332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete active episodic thinking task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete active episodic thinking task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete active future thinking priming task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete active future thinking priming task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete control episodic future thinking task
Study: NCT01215149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-ENV vaccine
Description: Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Description: Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
Study: NCT04297332

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Complete control episodic future thinking task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Complete control future thinking priming task

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Complete control future thinking priming task

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Provided with Forever Free relapse prevention booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Provided with Forever Free relapse prevention booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Provided with Forever Free relapse prevention booklet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Provided with Forever Free relapse prevention booklet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Receive nicotine patches, gum, or lozenges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Receive nicotine patches, gum, or lozenges

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement
Description: Receive nicotine patches, gum, or lozenges

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive coaching call

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive coaching call

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive coaching call

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Receive coaching call